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The marketing authorisation of a new medicine is granted on the basis of a favor-
able benefit-risk balance for its target population and indication. However, not all
risks will have been identified at the time when an initial authorisation is sought
and many of the risks associated with the use of a medicinal product will only be
discovered/fully characterised when the medicine is widely used in everyday med-
ical practice. A full HTA should provide for an evaluation of adverse drug reactions
(ADR) including those identified during long term follow- up or which are rare. In
addition to knowledge of risks, a relevant consideration for both individual pa-
tients and policy makers is the performance of risk minimization measures (RMM)
in everyday medical practice. The new European pharmacovigilance legislation
embeds the RMP as a key tool in proactive pharmacovigilance. The RMP, as the
documented set of pharmacovigilance activities and interventions designed to
identify, characterise, and prevent/minimise risks associated with exposure to a
medicine, may include specific RMM. RMM should be shown to achieve the desired
effect of reducing the burden of ADR and optimising health outcomes. Implemen-
tation of RMM may involve a substantial investment of resources and their perfor-
mance in health care systems should be assessed. In case a RMM proves ineffective,
alternative interventions must be identified implemented. We introduce an ap-
proach to evaluating the effectiveness of RMM that builds on the assessment of two
distinct levels of evidence. The evaluation of the effectiveness of RMM should
differentiate between the actual implementation of the RMM, and the attainment
of its final objective(s). If the RMM is unsuccessful, this strategy will help to ascer-
tain whether the intervention was inherently ineffective or badly delivered. The
assessment requires research encompassing analysis of implementation (process
indicators), and traditional epidemiological research addressing the attainment
(final outcome indicators) of RMM.
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Transforming the provision of health care involves collaboration and change on
many levels. Too often health care delivery decisions are made without consider-
ing the complex and dynamic nature of the health system. Approaching these
problems from a systems thinking perspective integrates these traits and encour-
ages long term thinking about solutions. Despite being widely used in other disci-
plines, only recently has systems analysis started to play a larger role in transform-
ing health care provision. The purpose of this work is to outline how systems
analysis tools can bridge multiple levels of health care to make more informed
decisions. The aforementioned will be illustrated using a Canadian case study.
Currently, a provincial strategy to diagnose and treat epilepsy in adults and chil-
dren in Ontario is being examined. The organization of epilepsy specific care cen-
tres (ESCC) into district and regional services is being recommended which will
modify current practice patterns and access to care. Subsequently, any changes in
delivery will have an impact on referral rates and patterns as well as resource
utilization (i.e. beds, staff, and diagnostic tests). The use of systems analysis tools
can bring insight into how the inter-relationship between ESCCs can be modeled
and how access to care will be affected and aid in capacity planning (i.e. resources
and costs).System changes can be graphically illustrated and quantified using the
systems analysis tool discrete event simulation. Mapping the clinical pathways
and patient flow of epileptic patients through the current system, a simulation
model was developed to help inform the planning process. This was useful in
understanding how the system might respond and in identifying potential bottle-
necks or where resources may be limited. Using discrete event simulation facili-
tated the ability to take on multiple perspectives by conducting analyses at multi-
ple institutional levels (i.e. government, hospital and health care practitioner).
PHP203
HOW TO OPTIMISE CHANCES FOR SUCCESSFUL AMNOG ASSESSMENTS – BEST
PRACTICE APPROACH FOR GERMAN MARKET ACCESS
Bonduelle D, Plantoer S
IMS GmbH & Co. OHG, Munich, Bavaria, Germany
Since the introduction of AMNOG in January 2011, manufacturers in Germany are
required to submit a “benefit dossier” and show additional benefit in relation to a
so-called appropriate comparative therapy to the Federal Joint Committee for every
NCE in order to gain access to price negotiations. If an additional benefit is shown,
the new reimbursed price will be a surplus on the reimbursed comparator price.
Market access in Germany changed significantly due to AMNOG and requires early
preparation, an interdisciplinary approach and clearly defined internal processes.
Market access strategies and processes have to be reviewed in light of the new
framework and adapted in order to optimize the chance to be successful in the
AMNOG process. Preparation for AMNOG should start as early as in the planning of
clinical studies to implement the right questions into the study and not to rely on
surrogate drivers. The FJC will respond best to data providing the most credible
scientific clinical evidence. Building RCTs powered to capture such information
does present important issues for pharmaceutical companies to address. Early
planning of clinical studies should be part of an early strategy development for the
NCE that can be informed by early phase modeling of the likely outcome of the
benefit assessment. Early identification of the patient groups that are most likely to
benefit is vital in order to plan for patient (sub-) populations big enough to achieve
statistical significant results and positive outcomes in the AMNOG process. An
interdisciplinary approach is required at a stage in the product development where
there are no common processes and communication paths established between
headquarter and affiliates. A best practice approach requires a well defined process
including road maps and checklists per stage of product development in form of
standard operating procedures in order to optimize market access.
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Public policies/interventions impact on many areas of activity including areas be-
yond the main focus of them ; the costs and (dis)benefits falling on other areas of
the economy, government and/or private sector, and different individuals. How-
ever, there is no consensus on the appropriate way to analyse such policies/inter-
ventions to decide which are beneficial and should be implemented. One form of
economic evaluation, cost-effectiveness analysis, has been widely used to inform
decisions about policies/interventions which affect only a single sector where
there is a single agreed output (as in most health care evaluations), however, its use
for evaluating interventions with multi-sector impacts is limited. Cost-benefit
analysis (CBA), another form of economic evaluation, based on welfarism, has been
proposed as a method which allows the evaluation of policies/interventions where
costs and benefits fall on several sectors, by aggregating costs and benefits into a
given numeraire, normally consumption. However, a key weakness of CBA is it fails
to acknowledge the relevance of sectors’ budget constraints. This despite the pro-
cess by which budget constraints are set being viewed as having (democratic)
legitimacy. We consider how decisions on policies/interventions with multi-sec-
toral impacts could most appropriately be informed by economic evaluation. Two
options are considered: first, where there is an implied or explicit social welfare
function (which could be based on welfarist or extra-welfarist principles); and
second, a societal decision making approach. We aim to demonstrate that trade-
offs are inevitable and have to be made, but budget constraints cannot be ignored
and shadow prices on budget constraints are central no matter which approach is
accepted. We also consider whether compensation payments between ‘losing’ and
‘gaining’ sectors are a potential means of understanding the net benefit associated
with policies with multi-sectoral effects, and whether it is possible, necessary or
even appropriate in practice to make such payments.
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That the world faces an epidemic of chronic diseases is unmistakable. Chronic
diseases represent 63% of all deaths worldwide. Against the background of demo-
graphic aging, the prevalence of comorbidity or multi-morbidity is as high as 60%
among individuals aged 55 to 74 years. In the context of financial crunch wrought
by the financial crisis, the financial and non-financial burden of chronic diseases
make their management a priority concern globally. Primary care plays a critical
role in dealing with this epidemic. To harness the full potential of primary care,
however, the way it is organized needs transformation. At present 1) primary care
is still organized around the primary care physician even as the shortage of pri-
mary care physician is worsening and is unlikely to improve in the immediate
future; 2) models of care for the chronically ill are directed to the management of
each disease separately, and despite its attribute of continuity, comprehensiveness
and patient-centeredness; 3) fails to harness the contribution of patient self-man-
agement even as role of patient involvement in their health and health care is
recognized; and 4) and overcome the barriers resulting from the structure of the
health care system. These challenges are true for primary care in low and middle-
income settings and high-income settings. A global framework for the transforma-
tion of primary care, consequently, offers promise to every health care system. The
critical elements of such involve 1) the development of primary care teams that
include physician services extenders such as primary care physicians or nurse
practitioners; 2) that will deal with the health needs of the population – rather than
the those of the individual patient; 3) by way of engaging chronically ill patients in
co-managing their condition; 4) using ehealth technologies and point-of-care-test-
ing facilities.
PHP206
ASSESSING THE VALUE OF ACCESS TO INDIVIDUAL PATIENT DATA FOR
REIMBURSEMENT DECISIONS
Manca A
University of York, Heslington, York, UK
To successfully support health care decision-making, cost-effectiveness analysis
(CEA) must consider and synthesise all (relevant) available evidence relating to the
clinical effectiveness, health-related quality of life (HRQoL) and costs of the health
technologies under scrutiny. Evidence based medicine tells us that statistical evi-
dence synthesis of multiple individual patient level data (IPD) sources (e.g. IPD
meta-analysis and its extensions) is the gold standard for deriving relative treat-
ment effect estimates, one of the key parameters in any cost-effectiveness model.
Unfortunately the evidence base available to the cost-effectiveness modeller is
often multifaceted and fragmented, comprising a mix of aggregate (AD, or sum-
mary level) and individual patient level data. This scenario poses a series of meth-
odological issues and it is not uncommon for the analyst to end up collapsing the
IPD into AD, with consequent loss of information, for use in a standard evidence
synthesis model (e.g. meta analysis or mixed treatment comparison of AD). Such a
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